Success Story: Hematology and Oncology Research Leads to NIW Approval in Just 54 Days With Direct Premium Processing
Client’s Testimonial:
"Awesome! Thank you so much.”
On June 9th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Hematology Oncology Fellow in the Field of Hematology and Oncology (Approval Notice).
General Field: Hematology and Oncology
Position at the Time of Case Filing: Hematology Oncology Fellow
Country of Origin: South Korea
State of Residence at the Time of Filing: Ohio
Approval Notice Date: June 9th, 2026
Processing Time: 1 month, 27 days (Premium Processing Requested)
Case Summary:
The client earned an M.D. and built a career combining clinical medicine, hematology, and oncology research, and patient-centered therapeutic development. At the time of filing, the client was conducting research in a U.S.-based medical research setting and had secured an upcoming assistant professor position in medicine with a focus on hematology and oncology.
North America Immigration Law Group (Chen Immigration Law Associates) presented the proposed endeavor as an effort to advance clinical and therapeutic strategies in hematology and oncology by integrating evidence-based research with patient-centered clinical practice. The goal was to improve outcomes and survival for individuals with blood disorders and cancer, including through research related to cancer treatment outcomes, CAR T-cell therapy safety, hematologic disease management, pancreatic cancer, and health disparities.
At the time of filing, the client's scholarly accomplishments included:
- 3 peer-reviewed journal articles
- 6 conference abstracts, including 2 first-authored abstracts
- 53 citations
- Research support from the National Eye Institute
Rather than presenting these metrics as isolated academic achievements, the petition demonstrated that the client’s work had practical value for improving clinical care and treatment decision-making. To establish national importance, the filing emphasized how cancer and hematologic disorders remain major public health challenges in the United States, with substantial effects on patient survival, healthcare quality, and long-term medical costs. The petition also explained that the client’s research had been relied upon by other researchers in studies involving antiviral intervention, oxidative stress, regenerative medicine, pancreatic cell function, CAR T-cell therapy, and renal safety in emerging cancer treatments.
The petition further showed that the client’s current and planned work aligned with national priorities in evidence-based cancer care, improved hematologic disease management, and safer therapeutic strategies. Two included expert letters also reinforced the client’s ability to continue contributing to hematology and oncology by explaining how the client’s research supported a stronger understanding of disease mechanisms, treatment-related complications, and clinical approaches for high-risk patient populations. One expert stated that: “There is thus no doubt that [Client] shall continue to produce additional valuable research, both driving progress in the field and bringing immense benefits to national and international concerns.”
Ultimately, this approval recognized the value of continued research aimed at improving cancer care, strengthening therapeutic safety, advancing hematology and oncology practice, and supporting better outcomes for patients with blood disorders and cancer in the United States.